Hengbo Medical is delighted to learn that Chengdu has unveiled the “top-level design” for the pharmaceutical and healthcare industry.

　　The pharmaceutical and healthcare industry is one of the most fiercely contested and strategically critical sectors worldwide. In recent years, Chengdu has continuously intensified its efforts to promote the pharmaceutical and healthcare industry, resulting in rapid and healthy growth. On July 1, reporters learned from the Municipal Commission of Economy and Information Technology that, in order to thoroughly implement the state, provincial, and municipal policies and decisions on high‑quality development, deepen supply‑side structural reform, and accelerate the building of a modern industrial system, Chengdu recently released the “Implementation Opinions on Promoting High‑Quality Development of Chengdu’s Pharmaceutical and Healthcare Industry” (hereinafter referred to as the “Implementation Opinions”). The document clearly states that Chengdu will speed up the development of a world‑class, trillion‑yuan modern pharmaceutical and healthcare industry system that boasts international competitiveness and strong regional driving power, striving to become a global hub for the pharmaceutical and healthcare industry.

　　The Implementation Opinions outline Chengdu’s development goals for the pharmaceutical and healthcare industry: with a global and future-oriented vision, taking supply-side reform as the main thread and leveraging the construction of industrial ecosystem and innovation value chains as key drivers, we will attract high‑end resources on a larger scale, deepen our integration into the international division of labor, and elevate the industry to a higher level, thereby accelerating the establishment of a world‑class, trillion‑yuan modern pharmaceutical and healthcare industry system that is both internationally competitive and regionally driving.

　　Build a globally renowned center for biomedical innovation and creation.

　　According to reports, in terms of development priorities, the Implementation Opinions adhere to the principle of “strengthening distinctive fields, enhancing advantageous areas, and seizing emerging fields,” focusing on 10 key areas including biopharmaceuticals, medical health, and pharmaceutical commerce. By benchmarking against world-class standards, the document aims to accelerate the establishment of a pharmaceutical and healthcare industry ecosystem that boasts prominent strengths, fosters integrated and mutually reinforcing development, enjoys robust growth, and possesses both international competitiveness and strong regional driving power.

　　In the field of medical and healthcare, the Implementation Opinions propose that Chengdu will become the premier destination for medical and healthcare services along the Belt and Road. Specifically, the city will focus on developing an internationally renowned medical center, establishing itself as a national hub for traditional Chinese medicine, building an international mecca for medical aesthetics, and creating a world‑famous wellness and health resort. In the pharmaceutical and trade sector, the Implementation Opinions call for the development of a pharmaceutical supply chain hub city with global influence.

　　Support the development of 18 functional zones related to the pharmaceutical and healthcare industries.

　　It is worth noting that, in order to coordinate city‑wide resource allocation, accelerate the improvement of industrial ecosystems encompassing innovation, enterprises, talent, and finance, enhance the multi‑dimensional integration and synergistic, transformative capabilities of the industrial ecosystem, and promote high‑quality development of Chengdu’s pharmaceutical and healthcare industry, Chengdu will systematically optimize industrial layout, precisely define industrial positioning and niche areas, and support the specialized, differentiated, and high‑end development of 18 functional zones related to the pharmaceutical and healthcare industry. Chengdu will expedite the establishment of an overarching spatial structure for the pharmaceutical and healthcare industry featuring “Three Cities, Three Zones, and Two Corridors,” with Chengdu Tianfu International Bio‑City, Chengdu Medical City, and Tianfu Chinese Medicine City serving as the primary pillars for building an international hub for biopharmaceutical innovation and creation, as well as a pharmaceutical supply chain hub city. The five central districts (including Chengdu High‑Tech South District), Chengdu Tianfu New Area, and the Eastward Expansion Zone will be developed into key supports for establishing Chengdu as the premier destination for international medical and healthcare services. Meanwhile, the Longmen Mountain–Qionglai Mountain International Demonstration Corridor for Traditional Chinese Medicine–Healthcare and Healthy Aging, and the Longquan Mountain International Demonstration Corridor for Health Tourism and Sports & Leisure will serve as the mainstays for developing Chengdu into an internationally renowned wellness and health resort destination.

　　In addition, world‑class industries require world‑class enterprises to provide the necessary support. To strengthen enterprise attraction and development, Chengdu will focus on attracting and cultivating enterprises that specialize in key product categories, cutting‑edge technologies, and high‑performing teams. The city will support enterprises in accelerating their global market expansion and pursuing cross‑border mergers and acquisitions both domestically and abroad, while encouraging them to obtain authoritative drug and medical device certifications from the World Health Organization and developed countries. By building production lines that meet international standards, Chengdu aims to enhance enterprises’ internationalization capabilities and foster the emergence of a group of world‑class industry leaders.

　　Promote pilot programs and trials.

　　Developing a “Chengdu Model” for Biopharmaceutical Industry Policies

　　In light of the unique characteristics of the pharmaceutical and healthcare industries and Chengdu’s specific realities, the Implementation Opinions also explicitly outline policy measures to strengthen factor guarantees and promote pilot programs and trials. Among these measures is the establishment of the Chengdu Pharmaceutical and Healthcare Industry Investment Fund, which will support the creation of venture capital and angel investment funds focused on the pharmaceutical and healthcare sector within industrial functional zones, guiding high‑quality projects to cluster in these zones. The document supports enterprises in leveraging multi‑tiered capital markets for financing, encourages banks to innovate in financing services such as equity‑debt linkages, supply chain finance, M&A loans, bank‑insurance collaborations, and loan products secured by intangible assets like intellectual property, and expands both the loan risk compensation fund for small, medium, and micro enterprises and the scale of emergency working capital for private enterprises. Furthermore, it aims to improve the service system for attracting top-tier, core talent and to refine various industry‑specific talent development programs, offering comprehensive services—including convenient access to schooling for children, employment opportunities for spouses, housing assistance, medical care, streamlined entry and exit procedures, and flexible stay and residence arrangements—to eligible high‑level professionals.

　　At the same time, policies have been introduced to support R&D and innovation in pharmaceuticals and medical devices, as well as to ensure the supply and proper use of generic drugs, thereby establishing the “Chengdu Model” for biopharmaceutical industry policies. Focusing on cutting-edge biopharmaceutical technologies and products that are pioneering, breakthrough‑oriented, and strategically significant, efforts are being made to actively secure priority review channels for innovative drugs and medical devices, promote the establishment of customs clearance ports for biological products and first‑time imported chemical drugs, and accelerate the development and operation of key testing and inspection platforms for radiopharmaceuticals, high‑end medical devices, and other critical areas. Innovative approaches are being explored in areas such as optimizing the national reimbursement drug list, deepening reforms of medical service pricing, and advancing medical insurance payment methods, all in order to drive high‑quality industrial development.

　　Chengdu Hengbo Medical Device Co., Ltd. is a professional manufacturer of millimeter wave and microwave therapy devices, and under the strong support of Chengdu’s government policies, it is jointly developing with Chengdu’s medical and healthcare industry.